Trevi Therapeutics has crossed from proof-of-concept into registrational execution on a single oral cough medicine, and the field around that medicine just emptied. Haduvio, an extended-release form of nalbuphine, started its first late-stage idiopathic pulmonary fibrosis cough trial in the second quarter after the Coral study posted statistically significant cough-frequency reductions across every dose. Weeks later a large rival P two X three program at a major respiratory company failed to replicate benefit and was halted. The equity is no longer a mid-stage option on a crowded mechanism. It is a funded late-stage claim on a condition with no approved therapy in the United States.
The April follow-on is what makes that claim financeable rather than theoretical. Net proceeds of $162 million closed after the underwriters took their full option. Cash and marketable securities then stood at $319 million. Management states that stack funds idiopathic pulmonary fibrosis development through a potential Food and Drug Administration decision and also covers the Lake refractory-cough study plus a planned interstitial-lung-disease program. Operating spend is already rising as the first Ocean trial and Lake enroll, so the cash figure is a runway, not a cushion for a commercial launch. The market is paying a multi-billion enterprise value for a still-unapproved tablet.
The second-quarter print is the first look at that higher spend. Research cost jumped as Coral wound down and Ocean, Lake, and supportive safety studies ramped. The open question is whether Coral's six-week effect size holds in longer, larger, parallel registrational trials, and whether Lake's sample-size look later this year keeps refractory cough as a real second shot rather than a science project.